The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

Variant: NM_001083962.1(TCF4):c.1727G>A (p.Arg576Gln)

CA16607615

381549 (ClinVar)

Gene: TCF4
Condition: Pitt-Hopkins syndrome
Inheritance Mode: Autosomal dominant inheritance
UUID: b79ddda3-bf1e-4cee-8b49-6cc1423ac1a7

HGVS expressions

NM_001083962.1:c.1727G>A
NM_001083962.1(TCF4):c.1727G>A (p.Arg576Gln)
NC_000018.10:g.55228999C>T
CM000680.2:g.55228999C>T
NC_000018.9:g.52896230C>T
CM000680.1:g.52896230C>T
NC_000018.8:g.51047228C>T
NG_011716.1:g.364631G>A
NG_011716.2:g.411995G>A
ENST00000354452.8:c.1727G>A
ENST00000635822.2:c.1607G>A
ENST00000635990.2:n.1407G>A
ENST00000636400.2:c.1655G>A
ENST00000636751.2:c.*1435G>A
ENST00000636822.2:c.1337G>A
ENST00000637115.2:c.*1605G>A
ENST00000637169.2:c.1079G>A
ENST00000637239.2:n.1782G>A
ENST00000637250.2:n.1421G>A
ENST00000637923.2:n.1325G>A
ENST00000638154.3:c.1754G>A
ENST00000643689.1:c.1337G>A
ENST00000674764.1:c.*1338G>A
ENST00000675707.1:c.1337G>A
ENST00000354452.7:c.1727G>A
ENST00000356073.8:c.1715G>A
ENST00000398339.5:c.2033G>A
ENST00000457482.7:c.1247G>A
ENST00000537578.5:c.1655G>A
ENST00000537856.7:c.1325G>A
ENST00000540999.5:c.1643G>A
ENST00000543082.5:c.1589G>A
ENST00000544241.6:c.1514G>A
ENST00000561831.7:c.1235G>A
ENST00000561992.5:c.1325G>A
ENST00000562680.5:n.5250G>A
ENST00000564228.5:n.1502G>A
ENST00000564403.6:c.1745G>A
ENST00000564999.5:c.1715G>A
ENST00000565018.6:c.1463G>A
ENST00000566279.5:c.1547G>A
ENST00000566286.5:n.1706G>A
ENST00000567880.5:n.1535G>A
ENST00000568673.5:c.1655G>A
ENST00000568740.5:c.1640G>A
ENST00000570177.6:c.1325G>A
ENST00000570287.6:c.1235G>A
ENST00000616053.4:c.1463G>A
ENST00000626466.1:n.750G>A
ENST00000626584.2:c.1067G>A
ENST00000629387.2:c.1727G>A
NM_001243226.2:c.2033G>A
NM_001243227.1:c.1655G>A
NM_001243228.1:c.1745G>A
NM_001243230.1:c.1706G>A
NM_001243231.1:c.1589G>A
NM_001243232.1:c.1514G>A
NM_001243233.1:c.1325G>A
NM_001243234.1:c.1247G>A
NM_001243235.1:c.1235G>A
NM_001243236.1:c.1235G>A
NM_001306207.1:c.1643G>A
NM_001306208.1:c.1502G>A
NM_003199.2:c.1715G>A
NM_001330604.2:c.1724G>A
NM_001330605.2:c.1337G>A
NM_001348211.1:c.1601G>A
NM_001348212.1:c.1325G>A
NM_001348213.1:c.1337G>A
NM_001348214.1:c.1232G>A
NM_001348215.1:c.1079G>A
NM_001348216.1:c.1247G>A
NM_001348217.1:c.1655G>A
NM_001348218.1:c.1655G>A
NM_001348219.1:c.1643G>A
NM_001348220.1:c.1640G>A
NM_001083962.2:c.1727G>A
NM_001243226.3:c.2033G>A
NM_001243227.2:c.1655G>A
NM_001243228.2:c.1745G>A
NM_001243231.2:c.1589G>A
NM_001243233.2:c.1325G>A
NM_001243234.2:c.1247G>A
NM_001243235.2:c.1235G>A
NM_001243236.2:c.1235G>A
NM_001330604.3:c.1724G>A
NM_001330605.3:c.1337G>A
NM_001348211.2:c.1601G>A
NM_001348212.2:c.1325G>A
NM_001348213.2:c.1337G>A
NM_001348214.2:c.1232G>A
NM_001348215.2:c.1079G>A
NM_001348216.2:c.1247G>A
NM_001348218.2:c.1655G>A
NM_001348219.2:c.1643G>A
NM_001369567.1:c.1727G>A
NM_001369568.1:c.1727G>A
NM_001369569.1:c.1724G>A
NM_001369570.1:c.1724G>A
NM_001369571.1:c.1715G>A
NM_001369572.1:c.1715G>A
NM_001369573.1:c.1712G>A
NM_001369574.1:c.1712G>A
NM_001369575.1:c.1655G>A
NM_001369576.1:c.1652G>A
NM_001369577.1:c.1652G>A
NM_001369578.1:c.1652G>A
NM_001369579.1:c.1652G>A
NM_001369580.1:c.1652G>A
NM_001369581.1:c.1652G>A
NM_001369582.1:c.1643G>A
NM_001369583.1:c.1643G>A
NM_001369584.1:c.1640G>A
NM_001369585.1:c.1640G>A
NM_001369586.1:c.1658G>A
NM_003199.3:c.1715G>A
NM_001243230.2:c.1706G>A

Pathogenic

Met criteria codes 7
PS3_Supporting PS2_Very Strong PS4_Supporting PM2_Supporting PP4 PP3 PM1

Evidence Links 2

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Rett and Angelman-like Disorders VCEP
The p.Arg576Gln variant in TCF4 has been reported as a de novo occurrence (biological parentage confirmed) in at least 2 individuals with Pitt-Hopkins syndrome (PMID 23033978, 28726809) (PS2_VS, PS4_supporting, PP4). The p.Arg576Gln variant in TCF4 is absent from gnomAD (PM2_supporting). In vitro binding assays have shown that this variant impacts protein function (PMID 22460224) (PS3_supporting). The p.Arg576Gln variant occurs in the well-characterized basic Helix-Loop-Helix domain of TCF4 (PM1). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). In summary, the p.Arg576Gln variant in TCF4 is classified as Pathogenic for Pitt-Hopkins syndrome based on the ACMG/AMP criteria (PS2_VS, PM1, PS4_supporting, PM2_supporting, PP3, PP4).
Met criteria codes
PS3_Supporting
In vitro binding assays have shown that this variant impacts homodimer and heterodimer formation (PMID 22460224).
PS2_Very Strong
The p.Arg576Gln in TCF4 has been reported as a confirmed de novo occurrence in at least 2 individuals with Pitt-Hopkins syndrome (PMID 23033978 and 28726809).

PS4_Supporting
Found in two patients with Pitt-Hopkins syndrome

PM2_Supporting
The p.Arg576Gln in TCF4 is absent from gnomAD.
PP4
The p.Arg576Gln in TCF4 has been reported as a confirmed de novo occurrence in at least 2 individuals with Pitt-Hopkins syndrome (PMID 23033978 and 28726809).

PP3
Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own.
PM1
The p.Arg576Gln variant occurs in the well-characterized basic Helix-Loop-Helix domain of TCF4.
Approved on: 2021-03-26
Published on: 2021-05-17
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.